Cat. No.: HY-N0036

Costunolide

Name: Costunolide
Brand: MedChemExpress
SKU: HY-N0036
Price: 56.00 USD
Availability: InStock
Rating: 5 (7 reviews)

(Synonyms: (+)-Costunolide; Costus lactone)

7 Cited Publications

Customer Review

Based on 7 publication(s) in Google Scholar

Costunolide ((+)-Costunolide) is a naturally occurring sesquiterpene lactone, with antioxidative, anti-inflammatory, antiallergic, bone remodeling, neuroprotective, hair growth promoting, anticancer, and antidiabetic properties. Costunolide can induce cell cycle arrest and apoptosis on breast cancer cells.

For research use only. We do not sell to patients.

Purity : 99.92%
CAS No.: 553-21-9
Formula: C₁₅H₂₀O₂
Molecular Weight:232.32

Storage:

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Costunolide Chemical Structure

CAS No.: 553-21-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Solvent & Solubility
- In Vitro
- In Vivo
Protocols (9)
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

Apoptosis^[2]^[3]

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	12.3 μM Compound: 1	Cytotoxicity against human A549 cell line Cytotoxicity against human A549 cell line	[PMID: 16766184]
C6	IC₅₀	4.1 μM Compound: 1	Cytotoxicity against rat C6 cells Cytotoxicity against rat C6 cells	[PMID: 26226279]
DU-145	IC₅₀	29.2 μM Compound: 1	Cytotoxicity against human DU145 cell line Cytotoxicity against human DU145 cell line	[PMID: 16766184]
HBL-100	IC₅₀	10.3 μM Compound: 1	Cytotoxicity against human HBL100 cell line Cytotoxicity against human HBL100 cell line	[PMID: 16766184]
HL-60	IC₅₀	2.1 μM Compound: 1	Cytotoxicity against human HL60 cells Cytotoxicity against human HL60 cells	[PMID: 26226279]
HL-60	IC₅₀	7.7 μM Compound: 2	Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry Cytotoxicity against human HL60 cells after 18 hrs by annexin-V labeling-based flow cytometry	[PMID: 22985027]
K562	IC₅₀	14.5 μM Compound: 1	Cytotoxicity against human K562 cell line Cytotoxicity against human K562 cell line	[PMID: 16766184]
KB	ED₅₀	0.57 μg/mL Compound: 4, Costunolide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 17336532]
KB	ED₅₀	2.46 μM Compound: costunolide	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 18329753]
KB	IC₅₀	28.9 μM Compound: 1	Cytotoxicity against human KB cell line Cytotoxicity against human KB cell line	[PMID: 16766184]
KG-1a	IC₅₀	4.1 μM Compound: 1	Cytotoxicity against human KG1a cells Cytotoxicity against human KG1a cells	[PMID: 26226279]
Macrophage	IC₅₀	1.2 μg/mL Compound: 9	Antiinflammatory activity in mouse macrophages assessed as LPS-induced nitric oxide production Antiinflammatory activity in mouse macrophages assessed as LPS-induced nitric oxide production	10.1039/C2MD20172K
MIA PaCa-2	IC₅₀	17.7 μM Compound: 1	Cytotoxicity against human MiaPaca2 cell line Cytotoxicity against human MiaPaca2 cell line	[PMID: 16766184]
NALM-6	IC₅₀	65 μM Compound: Costunolide	Inhibition of telomerase in human NALM6 cells by TRAP assay Inhibition of telomerase in human NALM6 cells by TRAP assay	10.1039/C0MD00241K
NIH3T3	IC₅₀	13.9 μM Compound: 1	Cytotoxicity against mouse NIH3T3 cell line Cytotoxicity against mouse NIH3T3 cell line	[PMID: 16766184]
PA-1	IC₅₀	10.6 μM Compound: 1	Cytotoxicity against human PA1 cell line Cytotoxicity against human PA1 cell line	[PMID: 16766184]
RAW264.7	IC₅₀	>50 μM Compound: 22	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 33939429]
SW-620	IC₅₀	7.8 μM Compound: 1	Cytotoxicity against human SW620 cell line Cytotoxicity against human SW620 cell line	[PMID: 16766184]
T-cell	IC₅₀	2.57 μM Compound: Cos	Immunomodulatory activity in C57BL/6 mouse mesenteric lymph node T cells assessed as inhibition of concanavalin A stimulated T-cell proliferation incubated for 68 hrs by CCK-8 assay Immunomodulatory activity in C57BL/6 mouse mesenteric lymph node T cells assessed as inhibition of concanavalin A stimulated T-cell proliferation incubated for 68 hrs by CCK-8 assay	[PMID: 37017305]

In Vitro

Costunolide inhibits the colony formation, migrative and invasive abilities of the H1299 cells in a dose or time dependent manner^[2].
Costunolide (6.7-215.2 μM; 24 hours) inhibits the viability of H1299 cells in a dose-dependent manner, with an IC₅₀ of 23.93 μM^[2].
Costunolide (12.0-48.0 μM; 48 hours) induces apoptosis in H1299 cells^[2].
Costunolide (12-48.0 μM; 6-12 hours) regulates metastasis- and proliferation-associated mRNA expression^[2].
Costunolide regulates epithelial-to-mesenchymal transition (EMT)-associated protein expression^[2].
Costunolide regulates c-Myc mediated apoptosis signaling and 14-3-3-mediated signaling pathways in breast cancer cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[2]

View Protocol

Cell Line:

H1299 cells
Concentration:

6.7 μM, 13.5 μM, 26.9 μM, 107.6 μM, 215.2 μM
Incubation Time:

24 hours
Result:

Inhibited the viability of H1299 cells (MTT assay).

Apoptosis Analysis^[2]

View Protocol

Cell Line:

H1299 cells
Concentration:

0 µM, 12.0 µM, 24.0 µM, 48.0 µM
Incubation Time:

48 hours
Result:

Significantly promoted apoptosis at 24.0 µM and 48.0 µM.

RT-PCR^[2]

View Protocol

Cell Line:

H1299 cells
Concentration:

0 µM, 12.0 µM, 24.0 µM, 48.0 µM
Incubation Time:

6 hours, 12 hours
Result:

Regulated the metastasis- and proliferation-associated mRNA levels in a dose-dependent manner.

Western Blot Analysis^[2]

View Protocol

Cell Line:

H1299 cells
Concentration:

0 µM, 12.0 µM, 24.0 µM, 48.0 µM
Incubation Time:

48 hours
Result:

Significantly inhibited the EMT of H1299 cells.

In Vivo

Costunolide (20 mg/kg; i.p; daily; for 30 days) inhibits breast cancer through c-Myc/p53 and AKT/14-3-3 pathway^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4 weeks old female BALB/c nude mice, MDA-MB-231 cells xenograft mouse models^[3]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection, daily, for 30 days
Result:

Reduced the expression levels of c-Myc and p-AKT and elevated the expression levels of p53 and p-14-3-3.

Chemical Information

CAS No. 553-21-9
Appearance Solid
Molecular Weight 232.32
Formula C₁₅H₂₀O₂
Color White to yellow
SMILES

O=C(O[C@@]1([H])[C@@]2([H])CC/C(C)=C/CC/C(C)=C/1)C2=C
Synonyms

(+)-Costunolide; Costus lactone
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
- Plants
- Compositae
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (7)

All Cell Proliferation/Viability AssayRT-PCRWBBio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Cell Mol Biol Lett

Costunolide reduces glycolysis-associated activation of hepatic stellate cells via inhibition of hexokinase-2. [Abstract]

2019 Aug 14:24:52. PMID: 31428167

Costunolide purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2019 Aug 14:24:52. [Abstract]

Costunolide reduces HSC activation. Primary rat HSCs at passages 3 through 5 were treated with Costunolide (0-30 μM) at the indicated concentrations for 24 h. MTT assay for evaluating cell viability, which is presented as a percentage of the control.

Costunolide purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2019 Aug 14:24:52. [Abstract]

Costunolide reduces HSC activation. Primary rat HSCs at passages 3 through 5 were treated with Costunolide (0-30 μM) at the indicated concentrations for 24 h. Real-time PCR for determining the mRNA expression of α-SMA and collagen I.

Costunolide purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2019 Aug 14:24:52. [Abstract]

Costunolide reduces HSC activation. Primary rat HSCs at passages 3 through 5 were treated with Costunolide (0-30 μM) at the indicated concentrations for 24 h. Western blot assay for determining the protein expression of α-SMA and collagen I with quantification of the blots.

Costunolide purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2019 Aug 14:24:52. [Abstract]

Costunolide blocks aerobic glycolysis in HSCs. Primary rat HSCs at passages 3 through 5 were treated with Costunolide (0-30 μM) at the indicated concentrations for 24 h. Measurement of glucose uptake using absorbance at 570/610 nm.

Costunolide purchased from MedChemExpress. Usage Cited in: Cell Mol Biol Lett. 2019 Aug 14:24:52. [Abstract]

Blockade of aerobic glycolysis contributes to the reduction in HSC activation by costunolide. Primary rat HSCs at passages 3 through 5 were treated with Costunolide (30 μM) and/or 2-DG at the indicated concentrations for 24 h. Real-time PCR for determining the mRNA expression of α-SMA and collagen I.
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Mol Cancer Ther

2026 Jul 15:10.1158/1535-7163.MCT-26-0182. PMID: 42456172
ACS Omega

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer. [Abstract]

2024 Feb 28;9(10):11870-11882. PMID: 38496939
Molecules

Costunolide Plays an Anti-Neuroinflammation Role in Lipopolysaccharide-Induced BV2 Microglial Activation by Targeting Cyclin-Dependent Kinase 2. [Abstract]

2020 Jun 19;25(12):2840. PMID: 32575562
Gene

Activation of p53 by costunolide blocks glutaminolysis and inhibits proliferation in human colorectal cancer cells. [Abstract]

2018 Dec 15:678:261-269. PMID: 30103008

Costunolide purchased from MedChemExpress. Usage Cited in: Gene. 2018 Dec 15:678:261-269. [Abstract]

Western blot analysis of mTOR phosphorylation at Ser2448 and Ser2481 with quantification.
SSRN

2023 Feb 27.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (430.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 25 mg/mL (107.61 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3044 mL

21.5220 mL

43.0441 mL

5 mM

0.8609 mL

4.3044 mL

8.6088 mL

10 mM

0.4304 mL

2.1522 mL

4.3044 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (8.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocols

All Cell Biology Signal Pathway Related Animals and Diseases

Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (287 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Dae Yong Kim, et al. Costunolide-A Bioactive Sesquiterpene Lactone with Diverse Therapeutic Potential. Int J Mol Sci. 2019 Jun; 20(12): 2926. [Content Brief]

[2]. Minyan Wei, et al. Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells. Oncol Rep. 2020 Jun;43(6):1986-1994. [Content Brief]

[3]. Zhangxiao Peng, et al. Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway.Sci Rep. 2017; 7: 41254. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	4.3044 mL	21.5220 mL	43.0441 mL	107.6102 mL
	5 mM	0.8609 mL	4.3044 mL	8.6088 mL	21.5220 mL
	10 mM	0.4304 mL	2.1522 mL	4.3044 mL	10.7610 mL
	15 mM	0.2870 mL	1.4348 mL	2.8696 mL	7.1740 mL
	20 mM	0.2152 mL	1.0761 mL	2.1522 mL	5.3805 mL
	25 mM	0.1722 mL	0.8609 mL	1.7218 mL	4.3044 mL
	30 mM	0.1435 mL	0.7174 mL	1.4348 mL	3.5870 mL
	40 mM	0.1076 mL	0.5381 mL	1.0761 mL	2.6903 mL
	50 mM	0.0861 mL	0.4304 mL	0.8609 mL	2.1522 mL
	60 mM	0.0717 mL	0.3587 mL	0.7174 mL	1.7935 mL
	80 mM	0.0538 mL	0.2690 mL	0.5381 mL	1.3451 mL
	100 mM	0.0430 mL	0.2152 mL	0.4304 mL	1.0761 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Costunolide

Publications Citing Use of MedChemExpress (MCE) Costunolide

All Endogenous Metabolite Isoforms